keyword
MENU ▼
Read by QxMD icon Read
search

metronomic chemotherapy

keyword
https://www.readbyqxmd.com/read/29772973/evaluation-of-metronomic-cyclophosphamide-chemotherapy-as-maintenance-treatment-for-dogs-with-appendicular-osteosarcoma-following-limb-amputation-and-carboplatin-chemotherapy
#1
Arata Matsuyama, Courtney R Schott, Geoffrey A Wood, Danielle Richardson, J Paul Woods, Anthony J Mutsaers
OBJECTIVE To determine the effectiveness of metronomic cyclophosphamide (MC) chemotherapy (primary treatment of interest) with adjuvant meloxicam administration as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. DESIGN Retrospective case series with nested cohort study. ANIMALS 39 dogs with a histologic diagnosis of appendicular osteosarcoma that underwent limb amputation and completed carboplatin chemotherapy from January 2011 through December 2015...
June 1, 2018: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/29749077/cabazitaxel-regimens-inhibit-the-growth-of-prostate-cancer-cells-and-enhances-the-anti-tumor-properties-of-pedf-with-various-efficacy-and-toxicity
#2
Courtney Jarvis, Thomas Nelius, Dalia Martinez-Marin, Souad R Sennoune, Stéphanie Filleur
BACKGROUND: Taxanes chemotherapies represent the major therapeutic alternative for symptomatic mCRPC. While docetaxel is the most commonly prescribed Taxane for mCRPC; cabazitaxel has been approved for patients unresponsive to docetaxel. Still mCRPC remains incurable and patients often experience severe side effects. Recently, the FIRSTANA trial first demonstrated the absence of superiority in overall survival between cabazitaxel and docetaxel in mCRPC patients. Inversely, different toxicity were reported suggesting that cabazitaxel may provide a first line treatment option for some patients urging for a deeper characterization of cabazitaxel mechanisms of action as well as a re-evaluation of cabazitaxel conventional dose and schedule...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29749011/rapid-lc-ms-ms-method-for-quantification-of-vinorelbine-and-4-o-deacetylvinorelbine-in-human-whole-blood-suitable-to-monitoring-oral-metronomic-anticancer-therapy
#3
Giuseppe Corona, Milena Gusella, Anna Gaspardo, Gianmaria Miolo, Laura Bertolaso, Elisa Pezzolo, Felice Pasini, Agostino Steffan, Donatella Caruso
A rapid and sensitive LC-MS/MS method for therapeutic drug monitoring oral vinorelbine (VRL) metronomic anticancer chemotherapy has been developed and validated. Analysis of VRL and its main active metabolite 4-O-deacetylvinorelbine (M1) was performed in whole blood matrix. Both analytes were extracted by protein precipitation and separated on an Onyx monolith C18, 50 x 2 mm column then quantified by positive electrospray ionization and multiple reaction monitoring mode. The LLOQ was 0.05 ng/mL for both VRL and M1...
May 10, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29733541/a-multicenter-phase-ii-trial-of-neoadjuvant-letrozole-plus-low-dose-cyclophosphamide-in-postmenopausal-patients-with-estrogen-receptor-positive-breast-cancer-jbcrg-07-therapeutic-efficacy-and-clinical-implications-of-circulating-endothelial-cells
#4
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single-arm neoadjuvant trial with letrozole and cyclophosphamide was conducted. Eligibility criteria included postmenopausal status, T2-4 N0-1, and estrogen receptor-positive breast carcinoma. Letrozole (2.5 mg) plus cyclophosphamide (50 mg) was given orally once a day for 24 weeks...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29721725/the-impact-of-metronomic-adjuvant-chemotherapy-in-patients-with-advanced-oral-cancer
#5
Ming-Yu Hsieh, Gene Chen, Dun-Cheng Chang, Su-Yu Chien, Mu-Kuan Chen
BACKGROUND: This study evaluated the efficacy of tegafur-uracil for advanced oral cancer. METHODS: From January 2008 to December 2013, clinical data from 356 patients with stage III or IV oral squamous cell carcinoma who received curative surgical resection and postoperative concurrent chemoradiotherapy, treated with or without tegafur-uracil, were analyzed from a prospectively designed database. Tegafur-uracil was orally administered to 114 of the 356 patients...
May 2, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29720885/successful-second-line-metronomic-temozolomide-in-metastatic-paraganglioma-case-reports-and-review-of-the-literature
#6
Isabel Tena, Garima Gupta, Marcos Tajahuerce, Marta Benavent, Manuel Cifrián, Alejandro Falcon, María Fonfria, Maribel Del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana Palasí, Pilar Bello, Alfredo Marco, José Luis Ponce, Juan Francisco Merino, Antonio Llombart, Alfredo Sanchez, Karel Pacak
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B ( SDHB ) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB -related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29682600/bevacizumab-with-metronomic-chemotherapy-of-low-dose-oral-cyclophosphamide-in-recurrent-cervical-cancer-four-cases
#7
Rose Isono-Nakata, Hiroshi Tsubamoto, Tomoko Ueda, Kayo Inoue, Hiroaki Shibahara
Standard chemotherapy for women with advanced or recurrent cervical cancer involves a combination of paclitaxel, platinum, and bevacizumab. However, for patients who experience anaphylaxis in response to paclitaxel or platinum, have permanent peripheral neuropathy, or develop early recurrence or progressive disease during first-line chemotherapy, the development of a non-taxane non-platinum regimen is mandatory. Clinical trials using anti-angiogenic treatment demonstrated favorable outcomes in cases of highly vascularized cervical cancer...
May 2018: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29614265/pharmacokinetic-pharmacodynamic-modeling-of-combination-chemotherapy-for-lung-cancer
#8
Louis T Curtis, Victor H van Berkel, Hermann B Frieboes
Chemotherapy for non-small cell lung cancer (NSCLC) typically involves a doublet regimen for a number of cycles. For any particular patient, a course of treatment is usually chosen from a large number of combinational protocols with drugs in concomitant or sequential administration. In spite of newer drugs and protocols, half of patients with early disease will live less than five years and 95% of those with advanced disease survive for less than one year. Here, we apply mathematical modeling to simulate tumor response to multiple drug regimens, with the capability to assess maximum tolerated dose (MTD) as well as metronomic drug administration...
March 31, 2018: Journal of Theoretical Biology
https://www.readbyqxmd.com/read/29589138/mutational-analysis-of-triple-negative-breast-cancers-within-the-international-breast-cancer-study-group-ibcsg-trial-22-00
#9
Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S Coates, Richard D Gelber, Meredith M Regan, Aron Goldhirsch, Massimo Barberis, Marco Colleoni
PURPOSE: We investigated the occurrence and the prognostic and predictive relationship of a selected number of somatic mutations in triple-negative breast cancer (TNBC) patients having known clinical outcomes treated within the IBCSG Trial 22-00. METHODS: A matched case-control sampling selected patients enrolled in the IBCSG Trial 22-00 who had TNBC tumors, based on local assessment. Cases had invasive breast cancer recurrence (at local, regional, or distant site) according to the protocol definition...
March 27, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29532546/adjuvant-continuous-metronomic-adriamycin-cyclophosphamide-followed-by-weekly-nab-paclitaxel-for-high-risk-early-stage-breast-cancer
#10
Eunpi Cho, Qian Wu, Lena Rubinstein, Hannah Linden, Julie Gralow, Jennifer Specht, Vijayakrishna Gadi, Georgiana Ellis
Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous G-CSF growth factor support for 12 weeks followed by weekly nab-paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities. The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 100 mg/m2 IV weekly...
March 13, 2018: Breast Journal
https://www.readbyqxmd.com/read/29526662/administration-of-temozolomide-comparison-of-conventional-and-metronomic-chemotherapy-regimens
#11
Nicolas Houy, François Le Grand
PURPOSE: We compare the Maximum Tolerated Dose (MTD) and Metronomic Chemotherapy (MC) protocols for temozolomide administration. We develop an innovative methodology for characterizing optimal chemotherapy regimens. METHODS: We use a PK/PD model based on Faivre et al. (2013) for the pharmacokinetics of temozolomide, as well as the pharmacodynamics of its efficacy. For toxicity, which is measured by the nadir of the normalized absolute neutrophil count, we formalize the myelosuppression effect of temozolomide with the physiological model of Panetta et al...
March 8, 2018: Journal of Theoretical Biology
https://www.readbyqxmd.com/read/29508493/survival-analysis-of-dogs-with-advanced-primary-lung-carcinoma-treated-by-metronomic-cyclophosphamide-piroxicam-and-thalidomide
#12
G Polton, R Finotello, S Sabattini, F Rossi, P Laganga, M E Vasconi, A Barbanera, K Stiborova, C Rohrer Bley, L Marconato
Unresectable or metastatic (advanced) primary pulmonary carcinoma (PPC) represents a therapeutic challenge where surgery may be contraindicated and the therapeutic role of maximum-tolerated dose (MTD) chemotherapy remains uncertain. This study was undertaken to explore the impact of metronomic chemotherapy (MC) in dogs with advanced PPC. Previously untreated dogs with advanced (T3 or N1 or M1) PPC, with complete staging work-up and follow-up data, receiving MC (comprising low-dose cyclophosphamide, piroxicam and thalidomide), surgery, MTD chemotherapy or no oncologic treatment were eligible for inclusion...
March 6, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29488406/intraperitoneal-chemotherapy-for-ovarian-cancer-using-sustained-release-implantable-devices
#13
Smrithi Padmakumar, Neha Parayath, Fraser Leslie, Shantikumar V Nair, Deepthy Menon, Mansoor M Amiji
Epithelial ovarian cancer (EOC) remains to be the most lethal of all gynecological malignancies mainly due to its asymptomatic nature. The late stages are manifested with predominant metastases confined to the peritoneal cavity. Although there has been a substantial progress in the treatment avenue with different therapeutic interventions, the overall survival rate of patients remain poor due to relapse and drug resistance. Areas covered: The pharmacokinetic advantages offered by intraperitoneal (IP) chemotherapy due to peritoneal-plasma barrier can be potentially exploited for EOC relapse treatment...
May 2018: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/29486983/phase-ii-trial-of-bevacizumab-plus-weekly-paclitaxel-carboplatin-and-metronomic-cyclophosphamide-with-or-without-trastuzumab-and-endocrine-therapy-as-preoperative-treatment-of-inflammatory-breast-cancer
#14
Antonella Palazzo, Silvia Dellapasqua, Elisabetta Munzone, Vincenzo Bagnardi, Manuelita Mazza, Giuseppe Cancello, Raffaella Ghisini, Monica Iorfida, Emilia Montagna, Aaron Goldhirsch, Marco Colleoni
BACKGROUND: Inflammatory breast cancer (IBC) is a rare and highly aggressive disease. A neoadjuvant regimen with chemotherapy and an antiangiogenic strategy was investigated. PATIENTS AND METHODS: Patients with primary or recurrent IBC who were candidates for neoadjuvant treatment received weekly carboplatin and paclitaxel plus bevacizumab every 3 weeks and oral metronomic cyclophosphamide for 6 months. Trastuzumab was added for patients with HER2+ tumors and endocrine therapy was added for patients with estrogen receptor and/or progesterone receptor ≥ 10% tumors...
February 2, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29485134/breast-cancer-metronomic-chemotherapy-for-elderly-and-or-frail-patients
#15
Diana Romero
No abstract text is available yet for this article.
May 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29435154/efficacy-of-granulocyte-macrophage-colony-stimulating-factor-combined-with-metronomic-paclitaxel-in-the-treatment-of-lewis-lung-carcinoma-transplanted-in-mice
#16
Nengping Zhu, Rongsheng Qin, Qin Zhang, Shaozhi Fu, Shanshan Liu, Yue Chen, Juan Fan, Yunwei Han
Metronomic chemotherapy in combination with immunotherapy is an attractive approach in cancer therapy. The purpose of the present study was to investigate the anti-tumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with metronomic paclitaxel (MET PTX) on Lewis lung carcinoma transplanted in mice. In the present study, tumor-bearing mice survival time and tumor growth were monitored. The day after the end of the treatment, white blood cells were counted, and the number and maturation of dendritic cell were determined by flow cytometry...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29433963/pertuzumab-and-trastuzumab-with-or-without-metronomic-chemotherapy-for-older-patients-with-her2-positive-metastatic-breast-cancer-eortc-75111-10114-an-open-label-randomised-phase-2-trial-from-the-elderly-task-force-breast-cancer-group
#17
Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altintas, Nathan Touati, Fatima Cardoso, Etienne Brain
BACKGROUND: Despite the high incidence of metastatic breast cancer and its related mortality in the elderly population, our knowledge about optimal treatment for older patients with cancer is far from adequate. We aimed to evaluate the efficacy of dual anti-HER2 treatment with or without metronomic chemotherapy in older patients with HER2-positive metastatic breast cancer. METHODS: We did a multicentre, open-label, randomised, phase 2 trial in 30 centres from eight countries in Europe, in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease, who were 70 years or older, or 60 years or older with confirmed functional restrictions defined by protocol, and had a life expectancy of more than 12 weeks and a performance status according to WHO scale of 0-3...
March 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29423067/inhibition-of-tumor-growth-by-cancer-vaccine-combined-with-metronomic-chemotherapy-and-anti-pd-1-in-a-pre-clinical-setting
#18
Annacarmen Petrizzo, Angela Mauriello, Antonio Luciano, Domenica Rea, Antonio Barbieri, Claudio Arra, Piera Maiolino, Marialina Tornesello, Vincenzo Gigantino, Gerardo Botti, Gennaro Ciliberto, Franco M Buonaguro, Maria Tagliamonte, Luigi Buonaguro
Tumor microenvironment (TME) is characterized by multiple immune suppressive mechanisms able to suppress anti-tumor effector cell immunity. Combinatorial strategies, including vaccine and immunomodulatory drugs, need to be developed for improved immunotherapy efficacy. A novel combinatorial approach was assessed in C57BL/6 mice injected with mouse melanoma B16F10 cells. A multi-peptide vaccine (PEPT) was combined with a low dose metronomic chemotherapy (MCT) and an anti-PD-1 checkpoint inhibitor (CI). Statistical analysis were performed with the unpaired two-sided Student's t -test and ANOVA...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29414305/immunogenic-chemotherapy-dose-and-schedule-dependence-and-combination-with-immunotherapy
#19
Junjie Wu, David J Waxman
Conventional cytotoxic cancer chemotherapy is often immunosuppressive and associated with drug resistance and tumor regrowth after a short period of tumor shrinkage or growth stasis. However, certain cytotoxic cancer chemotherapeutic drugs, including doxorubicin, mitoxantrone, and cyclophosphamide, can kill tumor cells by an immunogenic cell death pathway, which activates robust innate and adaptive anti-tumor immune responses and has the potential to greatly increase the efficacy of chemotherapy. Here, we review studies on chemotherapeutic drug-induced immunogenic cell death, focusing on how the choice of a conventional cytotoxic agent and its dose and schedule impact anti-tumor immune responses...
April 10, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29372245/assessing-metronomic-chemotherapy-for-progressive-pediatric-solid-malignant-tumors
#20
Xuemin Fang, Hajime Uno, Lee-Jen Wei
No abstract text is available yet for this article.
January 25, 2018: JAMA Oncology
keyword
keyword
33012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"